Germany: Biopharmaceutical Industry Sartorius Acquires Umetrics and Bioscience

Editor: Alexander Stark

Sartorius acquired through its subgroup Sartorius Stedim Biotech the company MKS Instruments AB (Umetrics) based in Malmö, Sweden. In addition, Sartorius completed the acquisition of U.S.-based Essen Bioscience signed on March 3, 2017, after receiving antitrust clearance.

Related Vendors

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
(Source: Sartorius)

Goettingen/Germany — Umetrics is a specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. The company has already been cooperating with Sartorius for around five years and, in 2017, plans to generate full-year sales revenue of around $ 15 million and a significant double-digit operating profit margin. Sartorius purchased the company for $ 72.5 million from the U.S. MKS Instruments Group.

By acquiring Essen Bioscience, the Sartorius Lab Products & Services Division is expanding its portfolio in bioanalytics, which it entered last year by acquiring Intelli Cyt, a cell screening specialist. Essen Bioscience is headquartered in Ann Arbor, Michigan, USA. For the current fiscal year, the company expects to generate annual sales revenue of around $ 60 million and a strong double-digit operating profit margin.

Guidance raised for fiscal 2017

For the Lab Products & Services Division, Group management projects that, considering the Essen Bioscience acquisition and assuming an overall stable economic environment, the company expects an increase of about 20 % to 24 % (previously about 6 % to 10 %). For the Bioprocess Solutions Division, Sartorius expects that sales will grow by about 9 % to 13 %.

“Through the five companies that we have acquired over the past nine months, we have further extended the footprint of both our Group divisions in biopharmaceutical applications considerably. Even though the market environment has leveled off to normal growth levels as expected, we are well on track to achieve our increased annual targets,” said Group CEO Joachim Kreuzburg.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent